EGFR and non-small cell lung carcinoma: The phase III FLAURA trial compared osimertinib with gefitinib or erlotinib in untreated EGFR mutation–positive (Ex19del or Ex21L858R) advanced-stage NSCLC and found overall superiority of osimertinib, with longer progression-free survival and OS [65,66].